2024
A Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care
Hakim H, Alexander C, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. A Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care. The Permanente Journal 2024, 28: 212-222. PMID: 39269215, PMCID: PMC11404665, DOI: 10.7812/tpp/23.152.Peer-Reviewed Original ResearchConceptsShared decision-makingOncology cliniciansSDM principlesPerceptions of shared decision-makingImprove health care outcomesPatient-centred care modelComprehensive cancer care centerLeadership buy-inPatient-centered careHealth care outcomesLung cancer careParticipants perceived benefitsHealth care environmentTeam member rolesNon-small cell lung cancer careThematic analysis of interview dataCancer care centerSimulation-based programAnalysis of interview dataCare modelCare outcomesCancer carePatient-centeredPatient experienceCare environmentBuilding Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program
Alexander C, Hakim H, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. Building Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program. The Permanente Journal 2024, 28: 200-211. PMID: 39269220, PMCID: PMC11404653, DOI: 10.7812/tpp/23.160.Peer-Reviewed Original ResearchConceptsShared decision-makingPractice settingsImplementation of shared decision-makingSDM trainingTraining programSimulation training programMultidisciplinary cliniciansCentered carePatient goalsPost-trainingClinician experienceFocus groupsClinical careSelf-efficacyParticipants' understandingClinician awarenessPostinterventionPilot studyActive participationParticipantsProgram designCareCliniciansBody of evidenceGrowing body of evidence
2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerCohort 2Cohort 1Breast cancerAndrogen biosynthesisAmylase/lipaseLimited clinical activityPrior chemotherapy regimenPrior chemotherapy regimensMedian treatment durationNausea/vomitingChemotherapy regimenChemotherapy regimensPrimary endpointObjective responseOverall survivalFemale patientsAndrogen receptorClinical activityGrade 3Targetable pathwaysPatientsTherapeutic targetAR modulationTreatment duration
2020
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerFirst-line ICI treatmentImmune checkpoint inhibitorsPD-L1 expressionPD-L1 testingNegative PD-L1 expressionHigh PD-L1 expressionCell lung cancerICI treatmentCheckpoint inhibitorsLung cancerDeath ligand 1 (PD-L1) expression statusElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsCell death ligand 1 (PD-L1) expressionExpression statusLow PD-L1 expressionPD-L1 expression statusDeath ligand 1 (PD-L1) expressionRetrospective cohort studyFirst-line treatmentLigand 1 expressionProportion of patientsReal-world careImpact of High-Quality Goals-of-Care Discussions on Oncologist Productivity.
Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky JP, Egorova N, Franco R, Bickell NA. Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity. JCO Oncology Practice 2020, 16: e290-e297. PMID: 32048945, DOI: 10.1200/jop.19.00381.Peer-Reviewed Original ResearchConceptsGOC discussionsAdvanced cancerPatient populationCare discussionsPractice settingsDifferent practice settingsOncologist characteristicsStudy patientsCommunity hospitalRural hospitalsPatientsOncologistsHigh-quality goalsRural settingsSignificant differencesHospitalCancerValue unitsHoursSettingPrognosisPopulationCommunication skillsVisits
2019
The impact of communication style on patient satisfaction
Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction. Breast Cancer Research And Treatment 2019, 176: 349-356. PMID: 31025271, DOI: 10.1007/s10549-019-05232-w.Peer-Reviewed Original ResearchConceptsPatient satisfactionSatisfaction scoresBrief demographic formPhysical health scoresHigh patient satisfactionPatient satisfaction scoresAdvanced practice providersRoutine followPatient pairsDoctor QuestionnaireResultsIn totalHospital satisfactionBreast centerHealth SurveyPractice providersHealth scoresMethodsThis studyPatientsConcordance scoreMixed effects modelsDemographic formScoresEmployment statusPearson correlationProvidersThirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement?
Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA. Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement? JCO Oncology Practice 2019, 15: e410-e419. PMID: 30925070, DOI: 10.1200/jop.18.00500.Peer-Reviewed Original ResearchConceptsHigher readmission ratesReadmission ratesMetastatic cancerPreventable readmissionsTeaching hospitalNew York State hospital dischargesThirty-day readmissionState hospital dischargeSkilled nursing facilitiesCompeting-risks modelReadmission likelihoodAdvanced diseaseDischarge homeDischarge dispositionHospital dischargeYounger patientsReadmission reduction effortsHospice dischargeFemale sexHospital typeReadmissionNursing facilitiesPatientsHealth needsYounger ageDisparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer
Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.Peer-Reviewed Original Research
2018
Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.
Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.Peer-Reviewed Original ResearchConceptsQuality of carePatient satisfactionClinical trialsSmilow Cancer HospitalUS academic centersCommunity oncology practicesPress Ganey scoresCenter physiciansAntineoplastic treatmentCancer HospitalOffice visitsCancer practiceTumor stagingCare centerOncology practiceTumor boardClinical careAcademic centersCase presentationPractice sitesCareCore measuresTrialsCommunity practiceClinical integrationSpeed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials as TopicFemaleFollow-Up StudiesHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNivolumabPractice Patterns, Physicians'PrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesConceptsNon-small cell lung cancerPivotal clinical trialsRenal cell carcinomaCell death 1 proteinEligible patientsImmune checkpoint inhibitorsDeath 1 proteinClinical trialsClinical practiceFDA approvalAgent treatmentCheckpoint inhibitorsAnti-PD-1 agentsFlatiron Health networkRetrospective cohort studyAge of patientsCell lung cancerClinical trial participantsCohort studyPatient ageYounger patientsMore patientsSuch patientsTrial evidenceCell carcinomaAssociation of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting. JAMA 2018, 320: 469-477. PMID: 30088010, PMCID: PMC6142984, DOI: 10.1001/jama.2018.9824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDNA, NeoplasmFemaleGenes, erbB-1GenomicsGenotypeHumansImmunotherapyLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingReceptor Protein-Tyrosine KinasesRetrospective StudiesSequence Analysis, DNASurvival AnalysisConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCommunity oncology settingCell lung cancerLung cancerOncology settingRoutine testingNonsquamous non-small cell lung cancerTargeted treatmentPropensity score-matched survival analysisStage IIIB/IVFlatiron Health databaseIIIB/IVRetrospective cohort studyThird-line treatmentFirst-line treatmentMinority of patientsUnadjusted mortality ratesEGFR/ALKCohort studyOverall survivalSecondary outcomesUnmatched cohortPrimary outcomeAntineoplastic treatment
2017
Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer
Adelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer. JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.Peer-Reviewed Original ResearchConceptsShort-term mortalityAdvanced cancerChance of deathLife carePrognostic toolNovel prognostic toolObjective prognostic toolSmilow Cancer HospitalDay of admissionElectronic health record dataMedian survival timeSubjective clinical assessmentHealth record dataPositive predictive valueMedian survivalHospitalized patientsMortality predictorsCancer HospitalPrognostication toolsClinical assessmentSurvival timePatientsPredictive valueCancerMortalitySpeaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care Discussions
Solomon R, Smith C, Kallio J, Fenollosa A, Benerofe B, Jones L, Adelson K, Gonsky JP, Messner C, Bickell NA. Speaking Up: How Patient and Physician Voices Shaped a Trial to Improve Goals-of-Care Discussions. The Patient - Patient-Centered Outcomes Research 2017, 10: 489-501. PMID: 28364384, DOI: 10.1007/s40271-017-0226-z.Peer-Reviewed Original ResearchConceptsPalliative care physiciansAdvanced cancerCare physiciansGOC discussionsOutcome measuresPhysician voicesOutcomes Research InstituteCancer benefitIntervention visitsCare discussionsCare conversationsOutcome measurementsPatient inputPatientsNovel interventionsPatient stakeholdersPhysician inputStudy designOncologistsEarly goalDisease managementPhysiciansPhysician stakeholdersIntervention designInterventionStandardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care Use
Adelson K, Paris J, Horton JR, Hernandez-Tellez L, Ricks D, Morrison RS, Smith CB. Standardized Criteria for Palliative Care Consultation on a Solid Tumor Oncology Service Reduces Downstream Health Care Use. JCO Oncology Practice 2017, 13: jop.2016.016808. PMID: 28306372, DOI: 10.1200/jop.2016.016808.Peer-Reviewed Original ResearchConceptsHealth care usePC consultationPalliative careHospice referralReadmission ratesAdvanced cancerCancer careOncology servicesCare useStandardized criteriaInpatient oncology serviceReceipt of chemotherapyAdvanced solid tumorsHigh symptom burdenPalliative care consultationProspective cohort studyLength of staySymptom controlCohort studySymptom burdenPrior hospitalizationOncologic careCare consultationsControl subjectsIntervention group
2016
Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.
Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.Peer-Reviewed Original ResearchConceptsDay of deathLife care expendituresLife careIntensive endCancer decedentsIntensive care unit admissionCare expendituresLife care interventionsCare unit admissionEmergency department visitsSEER-Medicare databaseLast monthProportion of decedentsHospital referral regionsExpenditure differencesHospital deathICU admissionUnit admissionDepartment visitsHospice enrollmentIntensive careHighest quintileLater chemotherapyHospice useLowest quintileTrends in end-of-life cancer care in the Medicare program
Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program. Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.Peer-Reviewed Original ResearchConceptsLife cancer careDay of deathAggressive endLife careCancer careHospital deathHospice enrollmentEmergency departmentIntensive care unit admissionEnd Results-Medicare dataAggressiveness of endLate hospice enrollmentLife chemotherapy useCare unit admissionHospital referral regionsResult of cancerProportion of beneficiariesChemotherapy useICU admissionUnit admissionED visitsPatient demographicsTumor characteristicsReferral regionsMedicare beneficiaries
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines
2005
Treatment of hot flushes in breast and prostate cancer
Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.Peer-Reviewed Original ResearchMeSH KeywordsAminesAntineoplastic Agents, HormonalBreast NeoplasmsCimicifugaContraindicationsCyclohexanecarboxylic AcidsDrug Therapy, CombinationElectroacupunctureExcitatory Amino Acid AntagonistsFemaleGabapentinGamma-Aminobutyric AcidHormone Replacement TherapyHot FlashesHumansMaleNeoplasms, Hormone-DependentOrchiectomyParoxetinePhytotherapyPlant PreparationsProstatic NeoplasmsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsHormone replacement therapyHot flushesBreast cancerReplacement therapyProstate cancerSelective serotonin reuptake inhibitorsChemotherapy-induced menopauseMenopausal age womenMainstay of treatmentThrombo-embolic eventsSerotonin reuptake inhibitorsHealthy menopausal womenCommon health problemHot flush symptomsQuality of lifeMedical castrationHormonal therapyOvarian suppressionAndrogen ablationPerimenopausal periodNonhormonal agentsReuptake inhibitorsSignificant morbidityCancer survivorsMenopausal women